Group B streptococcal vaccine - Pfizer

Drug Profile

Group B streptococcal vaccine - Pfizer

Alternative Names: GBS infection vaccine - Pfizer

Latest Information Update: 16 Nov 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Streptococcal infections

Most Recent Events

  • 26 May 2017 Pfizer plans a phase I/II trial for Streptococcal infections (Prevention) in USA (NCT03170609)
  • 19 Oct 2016 Preclinical trials in Streptococcal infections (Prevention) in USA (Parenteral) before October 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top